[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Anabio R&D\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":138},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,83,111],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100611474","oral-spray-bacillus-spore-probiotic-in-preventing-and-supporting-treatment-of-dental-caries-in-children-100611474",false,"NCT07241052","Oral-Spray Bacillus Spore Probiotic in Preventing and Supporting Treatment of Dental Caries in Children","Evaluating Safety and Efficacy of Oral-Spray Bacillus Probiotic (LiveSpo® Smile CARE) in the Prevention and Adjunctive Treatment of Dental Caries in Children","Inclusion Criteria:\n\n* Children (male or female) aged 7-10 years, currently enrolled in primary school (grades 2-4).\n* At least one decayed tooth (any stage) at the time of screening.\n* Commitment to comply with study requirements, including refraining from using any other probiotic products for the ear, nose, and throat that could affect study outcomes.\n* Written informed consent obtained from a parent or legal guardian.\n\nExclusion Criteria:\n\nParticipant-level exclusion:\n\n* Presence of severe chronic disease, allergy, or use of antibiotics within 1 month prior to study initiation.\n* Use of oral or throat probiotic sprays\u002Flozenges within the past 30 days (excluding gastrointestinal probiotics).\n* Participation in another clinical study within the past 30 days.\n* Acute oral conditions (e.g., abscess, severe gingivitis) interfering with examination or intervention.\n* Currently receiving dental treatment at specialized dental\u002Foral health facilities.\n* History of congenital immunodeficiency or infectious disease.\n* Psychiatric disorders or sleep disturbances.\n* Known sensitivity or allergy to components of the investigational product.\n\nTooth-level exclusion:\n\n* Hard tissue lesions not caused by dental caries.\n* Supernumerary teeth or teeth not part of the functional dental arch.\n* Carious teeth with pain lasting \\>10 seconds during examination.\n* Carious teeth with visible pulp hyperemia (high risk of pulp complications).\n* Teeth showing signs of pulp disease, pulp necrosis, or periapical pathology.\n* Teeth previously treated with endodontic therapy or permanently restored with crowns.\n* Primary teeth with mobility grade ≥2 (due to disease or natural exfoliation).",true,"ALL","7 Years","10 Years",{"count":21,"type":22},130,"ESTIMATED","INTERVENTIONAL",[25],"NA","Despite advances in oral health care, cavities remain highly prevalent worldwide, especially among children. Conventional treatment methods focus on removing damaged tooth tissue but fail to completely eliminate or control pathogenic bacteria in the oral cavity, leading to a high risk of caries recurrence in the same or adjacent teeth. Probiotics are a promising biological therapy that can help restore balance in the oral microbiome.\n\nAmong probiotics, Bacillus species are unique because they form spores that make them stable under harsh conditions, such as heat and storage. They can also produce enzymes and natural compounds with antibacterial, anti-inflammatory, and protective effects. These features make Bacillus probiotics strong candidates for oral health applications.\n\nThis study is designed to evaluate the safety and efficacy of an oral-spray probiotic containing Bacillus subtilis ANA48 and Bacillus clausii ANA39 (LiveSpo® Smile CARE) in preventing and supporting the treatment of tooth decay in children. We hypothesize that this probiotic spray, when used regularly, will be safe and well-tolerated, while effectively reducing harmful bacteria in the mouth, preventing the progression of cavities, and improving overall oral health.\n\nStudy Design:\n\n* Sample Size: 130 participants\n* Study Location: a primary school in Hanoi, Vietnam Intervention Description: A total of 130 eligible participants will be randomly assigned to two groups (n = 65 per group).\n\nPlacebo Group will receive a 0.9% NaCl physiological saline, spray twice daily (morning and afternoon). Each application consists of two sprays at three sites (both dental arches and the front teeth), for a total of six sprays per use, continued for three consecutive months.\n\nSmile Care Group will receive an oral-spray probiotics containing ≥ 1 billion CFU\u002FmL × 20 mL of Bacillus subtilis and Bacillus clausii (LiveSpo Smile CARE). The dosage, frequency, and duration of use will be the same as in the placebo group.\n\nAll participants will receive the same standard dental care throughout the study, including the use of identical toothpaste, supervised weekly fluoride rinsing with 0.2% sodium fluoride (NaF), and scheduled follow-up visits. The probiotic and placebo sprays will be packaged in blinded bottles and administered according to the study protocol to maintain objectivity.\n\nStudy Duration: 12-18 months",[28],"Dental Caries",[30,31,32,33,34,35],"Dental caries","Children","probiotics","Oral health","Oral-spray","Bacillus spores","RECRUITING","2026-06-04",{"date":39,"type":40},"2026-06-05","ACTUAL",{"date":42,"type":40},"2026-03-05",{"date":44,"type":22},"2027-05-01",{"name":46,"class":47},"Anabio R&D","INDUSTRY",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":48},"100623675","assessing-role-of-probiotics-in-children-aged-6-36-months-treated-for-pneumonia-100623675","NCT07399717","Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia","Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia at Phu Tho Provincial Obstetrics and Pediatrics Hospitals Within 2026-2027","Inclusion Criteria:\n\n* Children (male\u002Ffemale) aged 6-36 months diagnosed and hospitalized for treatment for pneumonia.\n* Parents or guradians of the children agree to participate in the study, explain, and sign the research consent form.\n\nExclusion Criteria:\n\n* Children who need ventilator support.\n* Children who have had rhinoplasty surgery, nasal ulcers, nasal polyps or any nasal deformity that affects the use of the study product.\n* Children who get transferred or leave the treatment unit (not for professional reasons).\n* Children who have experienced congenital immunodeficiency or infectious disease (eg, HIV).\n* Children who are concurrently participating in another clinical trial or participated in a clinical trial within 30 days before selection.\n* Children who are under long-term medication (more than 7 consecutive days) within 30 days before selection.\n* Children with allergy or hypersensitivity to any ingredient of the study product.","6 Months","36 Months",{"count":59,"type":22},330,[25],"The main questions this study aims to answer are:\n\n* Does using probiotic nasal spray (LiveSpo Navax containing Bacillus subtilis and Bacillus clausii, 1x10\\^9 CFU\u002FmL), with or without oral probiotics (LiveSpo Pregmom containing Bacillus subtilis, Bacillus clausii, and Bacillus coagulans, 3x10\\^9 CFU\u002F5 mL), help children recover better from pneumonia when added to standard medical treatment?\n* Does using these adjunctive probiotics support reduce the recurrence of respiratory and gastrointestinal symptoms after hospital discharge? Researchers will compare three groups of children to see whether probiotic nasal spray alone or probiotic nasal spray combined with oral probiotics works better than placebo.\n\nAll participants will receive standard medical treatment for pneumonia. In addition, they will be randomly assigned to one of three study groups to receive adjunctive probiotic support in 2 months:\n\n* Control group: receives a saline nasal-throat spray (0.9% NaCl) and oral placebo liquid (RO water).\n* Nasal probiotic group: receives a probiotic LiveSpo® Navax nasal-throat spray and oral placebo liquid (RO water).\n* Nasal plus oral probiotic group: receives a probiotic LiveSpo® Navax nasal-throat spray plus LiveSpo® Preg-Mom oral probiotic suspension.\n\nParticipants will:\n\n* Use a nasal-throat spray three times a day.\n* Take an oral liquid twice daily.\n* Start using the study products during their hospital stay and continue for 8 weeks (2 months) from admission.\n* Be followed by the study team during hospitalization and at Day 30 and Day 60 after admission. The probiotic and placebo products look, smell, and taste the same so that neither the parents nor the study staff know which product each child receives.",[63,64],"Pneumonia","Pneumonia in Children",[66,67,68,69,70,71,35,31,72,73],"Acute respiratory infection","Adjunctive Treatment","Prevention","Nasal-oropharyngeal","Probiotic spray","Oral probiotic suspension","Respiratory viruses","Bacterial co-infection","NOT_YET_RECRUITING","2026-02-03",{"date":77,"type":40},"2026-02-10",{"date":79,"type":22},"2026-01-26",{"date":81,"type":22},"2027-12-30",{"name":46,"class":47},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":16,"sex":17,"minAge":90,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":98,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":110,"locationsCount":48},"100612801","oral-spray-bacillus-spore-probiotics-for-periodontal-disease-prevention-and-supprotive-treatment-in-the-elderly-100612801","NCT07258303","Oral-Spray Bacillus Spore Probiotics for Periodontal Disease Prevention and Supprotive Treatment in the Elderly","Evaluating Safety and Efficacy of Oral-Spray Bacillus Spore Probiotics (LiveSpo Smile CARE) in Preventing and Supporting the Treatment of Periodontal Diseases in Elderly in Hanoi","Inclusion Criteria\n\n* Patients aged 35 years and older.\n* Patients diagnosed with periodontal disease based on clinical examination, including gingivitis and periodontitis.\n* Patients presenting with at least 10 natural teeth in the dental arch.\n* Patients with stable general health status and able to comply with study procedures.\n* Patients (or their legal guardians) who provide written informed consent and voluntarily agree to participate in the study.\n\nExclusion Criteria\n\n* Patients with unstable general health, acute systemic or oral diseases, or malignant conditions that may interfere with participation.\n* Patients who are currently receiving treatment for periodontal disease at specialized dental facilities.\n* Patients currently using any therapeutic or adjunctive products for the management of periodontal disease.","35 Years",{"count":92,"type":22},90,[25],"Periodontal diseases are strongly associated with dysbiosis of the oral microbiome within the biofilm. Key pathogens, including Streptococcus mutans, Aggregatibacter actinomycetemcomitans, and Porphyromonas gingivalis, contribute to caries progression and periodontal inflammation. Given the limitations of antibiotic use and their potential side effects, probiotics represent a promising biological approach to restore microbial balance and support oral health.\n\nIn this study, researchers propose that direct application of probiotic spray into the oral cavity is safe and effective in alleviating typical symptoms of periodontal disease, particularly by reducing pathogenic bacterial density.\n\nThe objective of this study is to evaluate the safety and efficacy of a oral-spray Bacillus spore probiotics (LiveSpo Smile CARE), containing Bacillus subtilis ANA48 and Bacillus clausii ANA39 at a concentration of ≥ 1 billion CFU\u002FmL x 20 mL formulation, for the prevention and supportive treatment of periodontal disease.\n\nStudy Design:\n\n* Sample Size: 90 participants\n* Study Location: an elderly care center in Hanoi, Vietnam\n\nIntervention Description: A total of 90 eligible participants will be randomly assigned to two groups (n = 45 per group).\n\n* The Placebo Group will receive 0.9% NaCl physiological saline, spray twice daily (afternoon and evening), with two sprays per application at three sites (both dental arches and the front teeth), totaling six sprays per use, for four consecutive weeks.\n* The Smile Care Group will receive an oral-spray probiotics containing ≥ 1 billion CFU\u002FmL × 20 mL of Bacillus subtilis and Bacillus clausii (LiveSpo Smile CARE), administered with the same dosage and frequency as the placebo group.\n\nAll participants will receive blinded, coded spray bottles to ensure objectivity. Both groups will be instructed to use the same standardized toothpaste during the study period. Caregivers will monitor the health status of participants and record relevant information in their medical records. During the study, caregivers will be instructed not to provide any additional probiotic oral care products or the solution contains similar components.\n\nStudy Duration: 12-18 months.",[96,97],"Periodontal Disease","Oral Deseases",[96,99,100,101,102,103],"The elderly","pathogenic bacterial densities","Bacillus","Spores","oral-spray probiotics","2026-01-19",{"date":106,"type":40},"2026-01-21",{"date":108,"type":40},"2025-12-20",{"date":44,"type":22},{"name":46,"class":47},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":16,"sex":17,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":123,"conditions":124,"keywords":127,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":135,"leadSponsor":137,"locationsCount":48},"100617566","effects-of-multi-strain-bacillus-spore-probiotics-on-growth-digestive-function-and-gut-microbiota-in-cesarean-delivered-neonates-100617566","NCT07320287","Effects of Multi-strain Bacillus Spore Probiotics on Growth, Digestive Function, and Gut Microbiota in Cesarean-Delivered Neonates","A Randomized, Blinded, Controlled Trial to Evaluate Effects of Multi-strain Bacillus Spore Probiotic Supplements (LiveSpo PREG-MOM and LiveSpo CONSY) on Growth Metrics, Prevention of Functional Gastrointestinal Disorders, and Modulation of the Gut Microbiota in Cesarean-Delivered Neonates","Inclusion Criteria:\n\n* Healthy term neonates delivered by cesarean section.\n* Infants were born at term, ranging from 38 to 40 weeks' gestation.\n* Birth weight appropriate for gestational age (AGA), defined as between the 10th and 90th percentiles for gestational age (≥P10 and ≤P90).\n* The infant's parent(s) or legal guardian(s) provide written informed consent and agree to comply with study procedures.\n\nExclusion Criteria:\n\nFor the neonate:\n\n* Multiple births (twins, triplets, etc.)\n* Birth weight outside the appropriate-for-gestational-age range: small for gestational age (SGA, \\\u003C P10) or large for gestational age (LGA, \\> P90).\n* Major congenital abnormalities affecting the hematologic, hepatobiliary, cardiovascular, renal\u002Furinary, or gastrointestinal systems; severe inborn errors of metabolism; or suspected primary immunodeficiency.\n* Prior exposure to systemic or enteral antibiotics (oral, IV, or IM) before the baseline assessment.\n* Known allergy or intolerance to any component of the investigational product.\n* Concurrent participation in another interventional clinical trial.\n* The investigators judge the neonate to be unsuitable for participation.\n* Parent(s) or legal guardian(s) who do not comply with study requirements or refuse to sign the informed consent.\n\nFor the mother:\n\n* Mother diagnosed with a serious or unstable medical condition involving the hepatobiliary, renal\u002Furinary, cardiovascular, respiratory, endocrine\u002Fmetabolic, or psychiatric systems.\n* Mother who intends to use, or is prescribed, any other probiotic\u002Fprebiotic product for herself or the infant during the study period.","0 Days","1 Day",{"count":121,"type":22},180,[25],"Infants born by cesarean section commonly show early weight loss and slower recovery of birth weight, together with characteristic patterns of gut microbiota dysbiosis marked by reduced Bifidobacterium and Bacteroides and increased Proteobacteria. This early microbial alteration has been associated with functional gastrointestinal disorders (FGIDs), including colic, regurgitation, and changes in stool frequency and consistency, which may in turn affect early growth and overall gastrointestinal functioning. Probiotic supplementation is considered a safe and feasible strategy to support microbial restoration and improve digestive function during the first months of life.\n\nIn this study, researchers propose that daily supplementation with multi-strain Bacillus spore probiotics may help support healthy early growth, reduce functional gastrointestinal symptoms, and promote a more balanced gut microbiota in cesarean-delivered infants.\n\nThe objective of this study is to evaluate the safety and efficacy of two oral probiotic formulations, LiveSpo PREG-MOM and LiveSpo CONSY, containing multi-strain B. subtilis ANA46, B. clausii ANA39, and B. coagulans ANA40 at respective 3 and 4 billion colony-forming units (CFU)\u002F5 mL ampoule, administered 1 ampoule daily, during the first 90 days of life. The study examines effects on growth, digestive symptoms, immune markers, and microbial composition.\n\nStudy Design: This randomized, blind, controlled clinical trial will enroll 180 healthy full-term cesarean-born infants at Hanoi Obstetrics and Gynecology Hospital.\n\nIntervention Description: Participants will be randomly assigned to three groups (n = 60 each). All groups will receive one 5-mL ampoule daily for 90 days: LiveSpo PREG-MOM, LiveSpo CONSY, or placebo. Stool samples will be collected at several follow-up time points to assess digestive health and microbial development. All products will be provided in blinded and coded packaging to maintain objectivity.\n\nStudy Duration: 12 months",[125,126],"Functional Gastrointestinal Disorders (FGIDs)","Weight Loss",[128,129,130],"Cesarean-born Infants","Gut Dysbiosis","Bacillus spore","2026-01-06",{"date":133,"type":40},"2026-01-07",{"date":133,"type":22},{"date":136,"type":22},"2027-01-07",{"name":46,"class":47},""]